StockNewsNow.com Publishes New SNNLive Video Interview with

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 14, 2015 at 8:45 AM

StockNewsNow.com Publishes New SNNLive Video Interview with Amarantus BioScience Holdings, Inc.

LOS ANGELES, CA --(Marketwired - December 14, 2015) - StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Gerald Commissiong, President and CEO of Amarantus BioScience Holdings, Inc. ( OTCQX : AMBS ), a biotechnology company developing product candidates in Regenerative Medicine and Orphan Diseases, according to the Company's website (see here: www.Amarantus.com ). The video interview was recorded at the LD Micro "Main Event" on December 2^nd , 2015 in Bel Air, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Year-End Review with Amarantus BioScience Holdings, Inc. -- Discusses Severe Burns, Parkinson's Clinical Trials, MANF Pre-Clinical Work and Diagnostics

You can follow Stock News Now on FACEBOOK , TWITTER , LINKEDIN , YOUTUBE , and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings ( OTCQX : AMBS ) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and Congenital Giant Hairy Nevus to support clinical development expansion into those areas. AMBS also has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer's aggression. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP) and retinal artery occlusion (RAO). AMBS also owns the discovery of neurotrophic factors (PhenoGuard^™ ) that led to MANF's discovery.

AMBS' Diagnostics division owns the rights to MSPrecise^® , a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test^® ) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit http://www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , Twitter and Google+ .

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature user-generated video, SNN-produced video like SNNLive CEO video interviews, as well as articles, and their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for -- all here on StockNewsNow.com.

Embedded Video Available: https://www.youtube.com/watch?v=ZJFauxzffVg

StockNewsNow.com info@stocknewsnow.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thai Wellness Shines at Global Summit in Phuket

The New Face of Luxury: Healing and Wellness Thailand's gearing up for a spotlight moment on the global stage, and they're flaunting their wellness card at the upcoming Global Wellness Summit (GWS) 2026 in Phuket. From November 10-13, the world's wellness bigwigs will descend on this tropical locale to experience firsthand what Thailand’s calling 'Healing is the New...

Embraer ADS Ratio Change: Impact on Investors

ADS Ratio Adjustments: What's the Big Deal? Well, here we go. Embraer, that Brazilian aerospace heavyweight, has just kicked up some dust with its latest move concerning American Depositary Shares (ADS). Now, don't expect any shock and awe value-explosion gimmicks, but there's a shift in the air. Understanding the Split Let's cut to the financial meat: Embraer’s mucking...

Service Pros Adds Windshield Repair to Lineup

Revving Up the Service Engine Alright, folks, buckle up because Service Pros Auto Glass, our local go-to for windshield replacements, is cranking up their game. They're stepping into the windshield repair arena across Florida and South Carolina, aiming to save you a buck and keep you safe behind the wheel. That's a double win if you ask me. A Closer Look at the Details...

Stora Enso Charts Ambitious Path with Demerger Plan

Setting the Stage for Strategic Shifts Alright, folks, Stora Enso, that old behemoth of the paper and forest game, is at it again, shaking things up in a way only veterans of the industry can. They're no strangers to the cutthroat nature of this business, and it looks like they're ready to roll the dice for a new chapter. Amid an inflation-induced rollercoaster where...

AppLovin Faces Class Action Amid Model Concerns

AppLovin's Day in the Hot Seat Look, it's not every day you see a tech darling like AppLovin take such a nosedive, but that's what's on the plate right now. The company is staring down a securities class action lawsuit. It’s a bumpy ride for folks who parked their cash in AppLovin between February and August 2026, expecting high-flying returns based on big promises of...

Intersignal's Braid 2.1 Unchains AI from the Cloud

Memory Capsules: A Game Changer in AI Intersignal LLC is stirring the AI pot again with its latest reveal, Braid 2.1. Right out of Fort Lauderdale, this edge AI power player is unleashing Memory Capsules, aiming to do away with the pesky cloud dependency for good. Picture this: your local AI instances now have the chops to carry a lasting, queryable memory—seriously,...

Royal Princess Docks New Features for Onboard Experience

Royal Princess Sets Sail Refreshed Ever imagine what goes on behind the scenes of a full-blown ship makeover? Well, the Royal Princess just strutted out of a two-week stint in the drydock like a queen in a new frock. This ain't just slapping a fresh coat of paint on the hull. We're talking the debut of the Sanctuary Collection, a whole new gamut of spots for guests to wet...

Gooru AI Unveils Platform to Scale Human Expertise

A New Wave of AI-Powered Solutions Hot off the press, Gooru AI's recent shindig in the heart of Dallas aimed to showcase something they call 'Digital Goorus.' Now that might sound like a newage tech gimmick but peel back the layers and you find an ambitious attempt to let folks spread their smarts without having to be everywhere all at once. Imagine being able to crack...

TDS and Array Set for Q3 Results Amid Market Curiosity

The Anticipation Builds for TDS and Array's Q3 Results Financial markets are buzzing like a caffeine-fueled trading floor about the upcoming third quarter results from Telephone and Data Systems, Inc. (NYSE: TDS) and its partner in digital endeavors, Array Digital Infrastructure, Inc. (NYSE: AD). Set to go live with their numbers on November 6, 2026, these companies are...

Membrane Chromatography Market Surges with Biologics Boom

Another Chapter in Chromatography: What's New? It's like this: membrane chromatography is getting its day in the sun, and it's about time we dive into why it's happening. Projected to scale up from $0.37 billion in 2026 to a neat $0.63 billion by 2031, we’re talking a solid 11.3% compound annual growth rate. It's a tale of tech advancements and rising demand for...